Announced on 1 June, Debut Biotechnology, Inc. plans to develop “the next generation of high-performing active ingredients” for beauty and personal-care products after raising $34bn in a Series B funding round led by L’Oreal SA’s venture capital fund BOLD. Debut says its fully vertically integrated capabilities make it unique in the biotech space. “Debut's proprietary Bio2Consumer platform spans ingredient discovery, cell-free, biofermentation, formulation, clinical trials and brand creation. The platform utilizes cell-free and advanced fermentation approaches such as continuous biomanufacturing to overcome the limitations of traditional methods, dramatically reducing the need for space, water, and expensive and unsustainable inputs,” according to the release.
Other investors in the round included Fine Structure Ventures, Material Impact, GS Futures, Cavallo Ventures, Cultivian Sandbox Ventures, ACVC Partners....
